Equity research analysts covering Autolus Therapeutics maintain an average 12-month consensus price target hovering between $8.63 and $8.95 per share, with higher-end projections reaching up to $10.00 to $11.00 and lower estimates near $5.00. These figures reflect projected commercial uptake and pipeline milestones, though individual targets adjust dynamically based on clinical and regulatory progress.